|
1
|
Shimosato Y, Kameya T, Nagai K and Suemasu
K: Squamous cell carcinoma of the thymus: An analysis of eight
cases. Am J Surg Pathol. 1:109–121. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Suster S and Rosai J: Thymic carcinoma. A
clinicopathologic study of 60 cases. Cancer. 67:1025–1032. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yano M, Sasaki H, Yokoyama T, Yukiue H,
Kawano O, Suzuki S and Fujii Y: Thymic carcinoma 30 cases at a
single institution. J Thorac Oncol. 3:265–269. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marx A, Shimosato Y, Kuo TT, et al: Thymic
neuroendocrine tumours. In: World Health Organization
Classification of Tumours. Pathology and genetics of tumors of the
Lung, Pleura, Thymus and Heart. Travis WD, Brambilla E,
Muller-Hermelink HK and Harris CC: (Lyon). IARC Press. 188–195.
2004.
|
|
5
|
Wick MR and Rosai J: Neuroendocrine
neoplasms of the mediastinum. Semin Diagn Pathol. 8:35–51.
1991.PubMed/NCBI
|
|
6
|
Ogawa F, Iyoda A, Amano H, Nezu K, Jiang
SX, Okayasu I and Satoh Y: Thymic large cell neuroendocrine
carcinoma: Report of a resected case - a case report. J
Cardiothorac Surg. 5:1152010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: Revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Socinski MA, Bondarenko I, Karaseva NA,
Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P,
Zhang H, et al: Weekly nab-paclitaxel in combination with
carboplatin versus solvent-based paclitaxel plus carboplatin as
first-line therapy in patients with advanced non-small-cell lung
cancer: Final results of a phase III trial. J Clin Oncol.
30:2055–2062. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koizumi W, Morita S and Sakata Y: A
randomized phase III trial of weekly or 3-weekly doses of
nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in
patients with previously treated advanced gastric cancer (ABSOLUTE
Trial). Jpn J Clin Oncol. 45:303–306. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chirgwin J and Chua SL: Management of
breast cancer with nanoparticle albumin-bound (nab)-paclitaxel
combination regimens: A clinical review. Breast. 20:394–406. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Desai N, Trieu V, Yao Z, Louie L, Ci S,
Yang A, Tao C, De T, Beals B, Dykes D, et al: Increased antitumor
activity, intratumor paclitaxel concentrations, and endothelial
cell transport of cremophor-free, albumin-bound paclitaxel,
ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res.
12:1317–1324. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lemma GL, Lee JW, Aisner SC, Langer CJ,
Tester WJ, Johnson DH and Loehrer PJ Sr: Phase II study of
carboplatin and paclitaxel in advanced thymoma and thymic
carcinoma. J Clin Oncol. 29:2060–2065. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Igawa S, Murakami H, Takahashi T, Nakamura
Y, Tsuya A, Naito T, Kaira K, Ono A, Shukuya T, Tamiya A, et al:
Efficacy of chemotherapy with carboplatin and paclitaxel for
unresectable thymic carcinoma. Lung Cancer. 67:194–197. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Takeda K, Hirai F, Yamanaka T, Taguchi K,
Daga H, Shimizu J, Kogure Y, Kimura T, Tanaka K, Iwamoto Y, et al:
A multicenter prospective study of carboplatin and paclitaxel for
advanced thymic carcinoma: West Japan Oncology Group 4207L. ASCO
Annual Meeting Abstracts. J Clin Oncol (Suppl). 31:75292013.
|
|
15
|
Kawashima Y, Inoue A, Sugawara S, Harada
M, Kobayashi K, Kozuki T, Kuyama S, Sakakibara T, Maemondo M,
Asahina H, et al: Phase II study of amrubicin (AMR) and carboplatin
(CBDCA) for invasive thymoma (IT) and thymic carcinoma (TC):
NJLCG0803. ASCO Annual Meeting Abstracts. J Clin Oncol (Suppl).
31:75302013.
|
|
16
|
Yoh K, Goto K, Ishii G, Niho S, Ohmatsu H,
Kubota K, Kakinuma R, Nagai K, Suga M and Nishiwaki Y: Weekly
chemotherapy with cisplatin, vincristine, doxorubicin, and
etoposide is an effective treatment for advanced thymic carcinoma.
Cancer. 98:926–931. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Agatsuma T, Koizumi T, Kanda S, Ito M,
Urushihata K, Yamamoto H, Hanaoka M and Kubo K: Combination
chemotherapy with doxorubicin, vincristine, cyclophosphamide, and
platinum compounds for advanced thymic carcinoma. J Thorac Oncol.
6:2130–2134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jackman DM and Johnson BE: Small-cell lung
cancer. Lancet. 366:1385–1396. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Onoda S, Masuda N, Seto T, Eguchi K,
Takiguchi Y, Isobe H, Okamoto H, Ogura T, Yokoyama A, Seki N, et
al: Thoracic Oncology Research Group Study 0301: Phase II trial of
amrubicin for treatment of refractory or relapsed small-cell lung
cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol.
24:5448–5453. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Murakami H, Yamamoto N, Shibata T, Takeda
K, Ichinose Y, Ohe Y, Yamamoto N, Takeda Y, Kudoh S, Atagi S, et
al: A single-arm confirmatory study of amrubicin therapy in
patients with refractory small-cell lung cancer: Japan Clinical
Oncology Group Study (JCOG0901). Lung Cancer. 84:67–72. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Groen HJ, Fokkema E, Biesma B, Kwa B, van
Putten JW, Postmus PE and Smit EF: Paclitaxel and carboplatin in
the treatment of small-cell lung cancer patients resistant to
cyclophosphamide, doxorubicin and etoposide: A non-cross-resistant
schedule. J Clin Oncol. 17:927–932. 1999.PubMed/NCBI
|
|
22
|
Iyoda A, Hiroshima K, Moriya Y, Takiguchi
Y, Sekine Y, Shibuya K, Iizasa T, Kimura H, Nakatani Y and Fujisawa
T: Prospective study of adjuvant chemotherapy for pulmonary large
cell neuroendocrine carcinoma. Ann Thorac Surg. 82:1802–1807. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamazaki S, Sekine I, Matsuno Y, Takei H,
Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Asamura H, et al:
Clinical responses of large cell neuroendocrine carcinoma of the
lung to cisplatin-based chemotherapy. Lung Cancer. 49:217–223.
2005. View Article : Google Scholar : PubMed/NCBI
|
